Overview

Innovax-ND-ILT is a veterinary vaccine used to protect chickens against three separate infections, caused by Newcastle disease (ND) virus, avian infectious laryngotracheitis (ILT) virus and Marek’s disease (MD) virus.

ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production.

MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs. Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body. Birds infected with MD virus can be carriers and shedders of the virus for life.

ILT virus infections can produce respiratory signs, decreased egg production, thin egg shells, lack of growth, neurological and ophthalmologic signs and death. Innovax-ND-ILT contains a live strain of turkey herpesvirus (strain HVT) which has been modified so that it will produce proteins from ND virus and ILT virus.

Innovax-ND-ILT is available as a concentrate and solvent to be made into a suspension for injection.

The vaccine can be given to one-day-old chicks as a single injection under the skin in the neck or directly into 18-19-day-old chicken eggs containing embryos (unhatched developing chicks).

Protection starts at 5 weeks of age for Newcastle disease, 4 weeks of age for ILT and 9 days post vaccination for Marek’s disease. Protection lasts for 62 weeks after vaccination for Newcastle disease and infectious laryngotracheitis and covers the entire risk period for Marek’s disease.

The medicine can only be obtained with a prescription.

For more information about using Innovax-ND-ILT, see the package leaflet or contact your veterinarian or pharmacist.

Innovax-ND-ILT is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. The vaccine contains a type of herpesvirus which does not cause disease in chickens but which is similar to the virus that causes MD. The virus in the vaccine has been modified so that it also makes proteins from ND and ILT viruses. When Innovax-NDILT is given to chickens, the animals’ immune system recognises the virus as ‘foreign’ and makes antibodies against its proteins. In the future if the animals are exposed to similar proteins the immune system will be able to respond more quickly. This will help protect the chickens against ND, ILT and herpesvirus infections like MD.

For MD, five laboratory studies were performed to evaluate the start of protection and the minimum requirement of 9 days could be shown for both routes of application using very virulent or virulent MDV challenges. Reduction of mortality, clinical signs and lesions caused by MD virus were demonstrated.

Eight studies were performed to determine start of protection for ND. The claim of 5 weeks is considered supported by the data presented, to reduce mortality and clinical signs of disease.

One study was performed to determine the start of protection for ILT. Vaccination of embryonated eggs or day-old birds resulted in adequate protection from clinical signs, lesions and mortality when challenged at 4 weeks of age.

No studies were performed to determine duration of immunity against MD since HVT causes a persistent infection, which is considered to provide protection for the entire risk period. Duration of immunity against ND was demonstrated at 62 weeks post vaccination, with 100% of birds protected from challenge with NDV Texas GB strain. With 93% protection from clinical signs, duration of immunity against ILTV was demonstrated at 62 weeks of age.

Efficacy was demonstrated in the field in one safety/efficacy semi-field trial for MD and one field trial for ILT.

No side effects were observed after vaccination with Innovax-ND-ILT.

Safety information has been included in the summary of product characteristics and the package leaflet for Innovax-ND-ILT, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.

As the vaccine is stored in liquid nitrogen, it is important that any handling is done in a well-ventilated area and that precautions are taken when preparing the vaccine. For further information see the summary of product characteristics.

The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption. It is also the time required after administration of a medicine before eggs may be used for human consumption.

The withdrawal period for meat and eggs from chickens treated with Innovax-ND-ILT is ‘zero’ days, which means there is no mandatory waiting time.

The European Medicines Agency decided that Innovax-ND-ILT’s benefits are greater than its risks and it can be authorised for use in the EU.

Innovax-ND-ILT received a marketing authorisation valid throughout the EU on 16 September 2020.

български (BG) (169.25 KB - PDF)

View

español (ES) (147.16 KB - PDF)

View

čeština (CS) (178.35 KB - PDF)

View

dansk (DA) (146 KB - PDF)

View

Deutsch (DE) (150.14 KB - PDF)

View

eesti keel (ET) (144.71 KB - PDF)

View

ελληνικά (EL) (174.23 KB - PDF)

View

français (FR) (147.82 KB - PDF)

View

hrvatski (HR) (179.57 KB - PDF)

View

italiano (IT) (145.91 KB - PDF)

View

latviešu valoda (LV) (184.05 KB - PDF)

View

lietuvių kalba (LT) (179.4 KB - PDF)

View

magyar (HU) (180.46 KB - PDF)

View

Malti (MT) (193.26 KB - PDF)

View

Nederlands (NL) (147.07 KB - PDF)

View

polski (PL) (181.27 KB - PDF)

View

português (PT) (147.96 KB - PDF)

View

română (RO) (179.47 KB - PDF)

View

slovenčina (SK) (170.5 KB - PDF)

View

slovenščina (SL) (176.86 KB - PDF)

View

Suomi (FI) (145 KB - PDF)

View

svenska (SV) (146 KB - PDF)

View

Product information

български (BG) (267.19 KB - PDF)

View

español (ES) (215.1 KB - PDF)

View

čeština (CS) (244.31 KB - PDF)

View

dansk (DA) (216.19 KB - PDF)

View

Deutsch (DE) (169.97 KB - PDF)

View

eesti keel (ET) (204.73 KB - PDF)

View

ελληνικά (EL) (266.81 KB - PDF)

View

français (FR) (214.64 KB - PDF)

View

hrvatski (HR) (212.97 KB - PDF)

View

íslenska (IS) (215.76 KB - PDF)

View

italiano (IT) (223.93 KB - PDF)

View

latviešu valoda (LV) (228.92 KB - PDF)

View

lietuvių kalba (LT) (220.62 KB - PDF)

View

magyar (HU) (225.72 KB - PDF)

View

Malti (MT) (244.67 KB - PDF)

View

Nederlands (NL) (224.59 KB - PDF)

View

norsk (NO) (215.74 KB - PDF)

View

polski (PL) (230.33 KB - PDF)

View

português (PT) (207.2 KB - PDF)

View

română (RO) (223.77 KB - PDF)

View

slovenčina (SK) (235.39 KB - PDF)

View

slovenščina (SL) (233.24 KB - PDF)

View

Suomi (FI) (211.9 KB - PDF)

View

svenska (SV) (232.34 KB - PDF)

View

Latest procedure affecting product information: IG/1348

18/03/2021

български (BG) (113.18 KB - PDF)

View

español (ES) (95.64 KB - PDF)

View

čeština (CS) (107.65 KB - PDF)

View

dansk (DA) (141.28 KB - PDF)

View

Deutsch (DE) (106.42 KB - PDF)

View

eesti keel (ET) (64.64 KB - PDF)

View

ελληνικά (EL) (87.69 KB - PDF)

View

français (FR) (64.88 KB - PDF)

View

hrvatski (HR) (89.12 KB - PDF)

View

íslenska (IS) (96.96 KB - PDF)

View

italiano (IT) (84.27 KB - PDF)

View

latviešu valoda (LV) (86.24 KB - PDF)

View

lietuvių kalba (LT) (86.82 KB - PDF)

View

magyar (HU) (136.64 KB - PDF)

View

Malti (MT) (88.11 KB - PDF)

View

Nederlands (NL) (78.11 KB - PDF)

View

norsk (NO) (78.76 KB - PDF)

View

polski (PL) (118.29 KB - PDF)

View

português (PT) (66.01 KB - PDF)

View

română (RO) (86.34 KB - PDF)

View

slovenčina (SK) (168.34 KB - PDF)

View

slovenščina (SL) (140.54 KB - PDF)

View

Suomi (FI) (67.87 KB - PDF)

View

svenska (SV) (67.55 KB - PDF)

View

Product details

Name of medicine
Innovax-ND-ILT
Active substance
Cell-associated live recombinant turkey herpesvirus (strain HVT/NDV/ILT) expressing the fusion protein of newcastle disease virus and the glycoproteins gD and gI of infectious laryngotracheitis virus
International non-proprietary name (INN) or common name
Marek's disease vaccine, Newcastle disease vaccine & infectious laryngotracheitis vaccine (live recombinant)
Species
  • Embryonated chicken eggs
  • Chicken
Anatomical therapeutic chemical veterinary (ATCvet) code
QI01AD

Pharmacotherapeutic group

Immunologicals for aves

Therapeutic indication

For active immunisation of one-day-old chicks or embryonated chicken eggs:

  • to reduce mortality and clinical signs caused by Newcastle disease (ND) virus,
  • to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ILT) virus and Marek’s disease (MD) virus.

Authorisation details

EMA product number
EMEA/V/C/005190
Marketing authorisation holder
Intervet International B.V.

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Opinion adopted
16/07/2020
Marketing authorisation issued
16/09/2020
Revision
1

Assessment history

This page was last updated on

How useful do you find this page?